The Role of Leptin in the Association between Obesity and Psoriasis

Jaehyeon Hwang1,†, Ju Ah Yoo2,†, Hyungkee Yoon1,†, Taekyung Han1, Jongchan Yoon1, Seoljun An1, Jae Youl Cho2,* and Jongsung Lee2,*

1Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, 2Molecular Dermatology Laboratory, Department of Integrative Biotechnology & Biocosmetics Research Center, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, 3Molecular Immunology Laboratory, Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, Republic of Korea

Abstract

Adipose tissue secretes many adipokines which contribute to various metabolic processes, such as blood pressure, glucose homeostasis, inflammation and angiogenesis. The biology of adipose tissue in an obese individual is abnormally altered in a manner that increases the body’s vulnerability to immune diseases, such as psoriasis. Psoriasis is considered a chronic inflammatory skin disease which is closely associated with being overweight and obese. Additionally, secretion of leptin, a type of adipokine, increases dependently on adipose cell size and adipose accumulation. Likewise, high leptin levels also aggravate obesity via development of leptin resistance, suggesting that leptin and obesity are closely related. Leptin induction in psoriatic patients is mainly driven by the interleukin (IL)-23/helper T (Th) 17 axis pathway. Furthermore, leptin can have an effect on various types of immune cells such as T cells and dendritic cells. Here, we discuss the relationship between obesity and leptin expression as well as the linkage between effect of leptin on immune cells and psoriasis progression.

Key Words: Obesity, Psoriasis, Leptin, Adipose tissue, Pro-inflammatory cytokines

INTRODUCTION

The worldwide obesity rate has tripled since 1975, and is now reported to be one of the major causes of several immune and metabolic diseases. Consequently, obesity has become a national concern. According to WHO statistics in 2016, about 2 billion adults, globally, were overweight and over 650 million of those overweight adults were obese.

Adipose tissue is a type of energy-storage tissue that is closely associated with obesity, this association has led to it being considered to be, not only an endocrine gland, but also an immune organ that produces several kinds of immune cells, including macrophages, neutrophils, mast cells, eosinophils, and T and B cells (Huh et al., 2014; Vieira-Potter, 2014). In adipose tissue, adipocytes secrete various types of cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, leptin, IL-6, and IL-17 (Mohamed-Ali et al., 1998; Ahima and Flier, 2000). Importantly, several studies have argued that adipose tissue is an immune organ because it produces various inflammatory-related cytokines (Table 1) (Guzik et al., 2006; Poeggeler et al., 2010). When people or animals become obese, macrophages accumulate in adipose tissue and cytokine secretion significantly increases (Schenk et al., 2008; Kosteli et al., 2010). Thus, obesity enhances levels of various pro-inflammatory cytokines, which cause obesity-related metabolic diseases or inflammatory diseases by activating various pathways (Weisberg et al., 2003; Xu et al., 2003; Fain, 2010; Ouchi et al., 2011).

Adipocytes produce one of the main adipokines, Leptin which is encoded by the LEP gene (Scotece et al., 2014). Leptin is activated by the class I cytokine receptor, “leptin receptor” (LEPR or Ob-R). LEPR has at least six forms of cytoplasmic domain (Münzberg and Morrison, 2015). Several forms of LEPR activate various signaling pathways, such as...
as p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), Janus kinase (JAK), extracellular signal–regulated kinase (ERK) 1/2, protein kinase C (PKC), signal transducer and activator of transcription (STAT), and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB). These activated signaling pathways can regulate appetite by inhibiting orexigenic neuropeptides and inducing anorexigenic factors (Al-Suhaimi and Shehzad, 2013; Rosenbaum and Leibel, 2014). Thus, leptin is an important metabolic factor. Interestingly, because leptin secretion increases dependently on adipose cell size and adipose accumulation, obesity leads to high leptin levels (Poeggeler et al., 2010). In fact, high leptin levels can develop leptin resistance, which aggravates obesity (Enriori et al., 2006), demonstrating the close relationship between leptin and obesity.

**OBESITY AND LEPTIN**

In an endogenous hyperleptinemia state, leptin does not function properly, leading to increased food intake, impaired nutrient absorption, and inhibition of peripheral functions such as lipid and glucose metabolism (Sáinz et al., 2015). This is called leptin resistance, and its mechanism can be broadly divided into three categories: gene mutation, blood–brain barrier (BBB) permeability, and impairment of leptin receptor signaling (Gruzdeva et al., 2019). First, there have been cases where structural changes in the leptin molecule occur due to a single-gene mutation in an OB gene encoding leptin. This can cause overeating or congenital obesity, but is observed very rarely and is not considered a major cause of leptin resistance (Gruzdeva et al., 2019). Next, leptin resistance can develop when transport of leptin through the BBB is decreased, which makes it difficult to recognize leptin circulating in the hypothalamus (Yang and Barouch, 2007). Circulating leptin is bound by leptin receptors expressed in brain blood vessels and transferred from the blood to the brain and cerebrospinal fluid. It maintains energy balance through a network formed between the inner and outer neurons of the hypothalamus (Zhou and Rui, 2013). With high levels of leptin in the blood, leptin concentration is low in brain tissue, cerebrospinal fluid, and even spinal fluid. This implies that a high circulating leptin concentration accelerates leptin resistance and obesity by reducing BBB permeability (Gruzdeva et al., 2019). Finally, impairment of the intracellular signaling cascade of the leptin receptor can cause leptin resistance. Hypothalamic inflammation and endoplasmic reticulum stress caused by obesity also mediate leptin receptor signaling. For example, reducing endoplasmic reticulum stress or blocking inflammatory signals can enhance leptin signaling in obesity (Myers et al., 2010).

**PSORIASIS**

Psoriasis is a chronic autoimmune skin disease characterized by abnormal skin patches that appear red, dry, itchy, and scaly (Menter et al., 2008a). Psoriasis is estimated to affect approximately 125 million people around the world and oc-
curs in any age group (Parisi et al., 2013). Its symptoms vary by age, region and race, and are thought to be triggered by a combination of environmental and genetic factors. Psoriasis is associated with being overweight or obese, and obesity is more prevalent among psoriatic people than non-psoriatic people. Being overweight is a contributing risk factor for psoriasis development, and obesity significantly enhances this risk (Naldi et al., 2008). Body mass index (BMI) ≥25 kg/m² was considered a long-term predicted clinical risk factor for psoriasis (Sakai et al., 2005).

Current pathogenic psoriasis models start with an environmental trigger and/or loss of tolerance, which activates the following pathway: plasmacytoid dendritic cells (pDCs) and IL23-producing dermal dendritic cells (DCs) produce pro-inflammatory cytokines, like IL-23, which causes polarization and expansion of T17 cells. Activated T17 cells express main cytokines such as TNF-α, IL-17, IL-26, IL-29, which act on many types of cytokines and immune cells involved in psoriasis development, many therapeutics are useless. Consequently, narrow immune-targeting drugs that suppress specific subsets of T cells, and which are more effective and safer for repeated treatments, are commonly used (Kim and Krueger, 2017). Treatments that targeted monoclonal antibodies, such as infliximab (Inflectra®)/Janssen (Beerse, Belgium), ustekinumab (Stelara®)/Janssen (Beerse, Belgium), secukinumab (Cosentyx®)/Novartis (Basel, Switzerland) and brodalumab (Siliq®)/Valeant (Laval, Canada), are available as psoriasis treatments. These drugs were approved by the US Food and Drug Administration. Before the late 1990s, common psoriasis treatments included topical drugs, like methotrexate or cyclosporine, which have significant toxicities when administered chronically, and narrowband ultraviolet B/psoralen ultraviolet A (NB-UVB/PJVA) light therapy. These drugs were available as psoriasis treatments, but they were toxic when used repeatedly over many years (Stern, 2001). By the late 1990s, studies began to argue that consistent infiltration by T lymphocytes caused psoriasis (Lowes et al., 2003). In 2003, the first "broad" immune-targeting agents, alefacept and efalizumab, were approved by the US Food and Drug Administration. Because there are many types of cytokines and immune cells involved in psoriasis development, many therapeutics are useless. Consequently, narrow immune-targeting drugs that suppress specific subsets of T cells, and which are more effective and safer for repeated treatments, are commonly used (Kim and Krueger, 2017). Treatments that targeted monoclonal antibodies, such as

### Table 2. Current therapeutics for psoriasis treatment.

| Target | Name/Company | Route | Efficacy | References |
|--------|--------------|-------|----------|------------|
|        |              |       | Week PASI75 PASI90 |            |
| TNF    | Adalimumab (Humira®)/AbbVie (IL, USA) | SC | 16 | 71.0 45.0 | Menter et al., 2008b; Saurat et al., 2008 |
|        | Etanercept (Enbrel®)/Amgen (CA, USA) | SC | 12 | 47.3 20.9 | Leonardi et al., 2003; Papp et al., 2005; Tying et al., 2006 |
|        | Infliximab (dyyb/abda) (Remicade®)/Janssen (Beerse, Belgium) | IV | 10 | 75.5 45.2 | Reich et al., 2005; Menter et al., 2007 |
|        | Certolizumab pegol (Cimzia®)/UCB (Brussels, Belgium) | SC | 12 | 66.4 44.7 | Mease et al., 2014 |
|        | Ustekinumab (Stelara®)/Janssen | SC | 16 | 81.0 57.1 | Gordon et al., 2015 |
| IL-12/IL-23 p40 | Ustekinumab (Stelara®)/Janssen | SC | 16 | 74.4 52.4 | Papp et al., 2015 |
| IL-23 p19 | Gusekumab (Tremfya®)/Janssen | SC | 16 | 81.0 57.1 | Gordon et al., 2015 |
|        | Tildrakizumab-asnm (Ilumya®)/SUN (Mumbai, India)/Merck | SC | 16 | 74.4 52.4 | Papp et al., 2015 |
|        | Risankizumab/AbbVie | SC | 12 | 92.3 53.8 | Krueger et al., 2015 |
| IL-17  | Secukinumab (Cosentyx®)/Novartis (Basel, Switzerland) | SC | 12 | 77.1 54.2 | Leonardi et al., 2008 |
|        | Ixekizumab (Taltz®)/Eli Lilly (IN, USA) | SC | 12 | 87.3 68.1 | Griffiths et al., 2015 |
|        | Brodalumab (Siliq®)/Valeant (Laval, Canada) | SC | 12 | 85.1 86.3 | Lebwohl et al., 2015 |

FDA, US Food and Drug Administration; IL, interleukin; IV, intravenous; PASI75, reduction of 75–89% in Psoriasis Area and Severity Index; PASI90, reduction of at least 90% on Psoriasis Area and Severity Index; SC, subcutaneous; TNF, tumor necrosis factor.
as TNF-α antagonists, failed to elicit a primary response or maintain gradual efficacy (Hawkes et al., 2018). Current therapeutics for psoriasis show that the IL23/helper T (Th)17 axis pathway is very important in psoriasis. In fact, TNF-targeting drugs are less effective than IL23- or IL17-targeting drugs (Table 2). The Psoriasis Area Severity Index (PASI) is the most widely used tool to measure psoriasis. Achieving clear skin in affected areas is the purpose of psoriasis therapy. A PASI score of 75 means that a patient achieved 75% symptom improvement, and a PASI score of 90 indicates a 90% reduction in symptoms (Fredriksson and Pettersson, 1978). We will focus our discussion on pathologies of the IL23/Th17 axis pathway (Fig. 1).

**OBESITY, PSORIASIS, AND LEPTIN**

Leptin affects appetite and is one of the major adipokines associated with obesity. Leptin also affects immune cells, including dendritic cells (DC), neutrophils, natural killer (NK) cells, and T and B cells, through leptin receptors located on the surface of immune cells, and regulates the production of various cytokines. These signaling patterns induce a wide range of physiological effects by altering immune and inflammatory responses (Scotece et al., 2014). In particular, leptin-induced changes in various immune cells and the production of various cytokines are considered a main factor in psoriasis development, one of the most common inflammatory immune diseases. Consequently, in this review, the effects of leptin on the immune cells and cytokines involved in the pathogenesis of psoriasis were discussed and summarized (Table 3). We also consider that leptin may be an important signaling transducer, linking obesity and psoriasis.

**LEPTIN AND CYTOKINES**

Leptin affects the immune cells and cytokines involved in the pathogenesis of psoriasis. Granulocytes are affected by leptin, which acts as a survival cytokine. Leptin strongly activates granulocytes by stimulating chemokines and delaying apoptosis (Suzukawa et al., 2011; Sun et al., 2013). Monocyte and macrophages are also affected by leptin. Leptin increases the proliferation of monocytes in vitro and enhances their activation by inducing the production of TNF-α and IL-6 and stimulation of surface markers (e.g., cluster of differentiation [CD] 25, HLA-DR, CD 38, CD 71) (Santos-Alvarez et al., 1999). Leptin increases M1 phenotype macrophages that can produce pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β. In contrast, leptin decreases apoptosis of dendritic cells and upregulates expression of TNF-α, IL-1β, IL-6, IL-12, and MIP-1α; it also contributes to improvement of immature DC migration and chemotactic responsiveness. In addition, leptin promotes CD4+ T cell polarization, leading to a Th1 response (Fig. 2) (Mattioli et al., 2005). Finally, leptin exerts a negative effect on Treg proliferation as well as increasing pro-inflammatory cytokines (IL-6, IL-1β, IL-12, TNF-α, and IL-17).

**LEPTIN, RESISTIN, AND ADIPONECTIN IN PSORIASIS**

In addition to leptin, there are other adipokines such as resistin and adiponectin. These adipokines contribute to immune and inflammatory processes. Leptin and resistin increase the expression of proinflammatory cytokines such as TNF-α and CXCL8, whereas adiponectin is an anti-inflammatory adipokine (Kyriakou et al., 2018). Accordingly, many studies have investigated circulating concentrations of adipokines in patients with psoriasis. Meta-analysis of such studies showed that leptin and resistin levels in patients with psoriasis are higher than they are in the general population, while adiponectin concentrations are lower (Kyriakou et al., 2017). This result suggested a relationship between psoriasis and metabolic syndrome or obesity. In contrast, researchers have also investigated the effects of topical and systemic treatment on circulating adipokine concentrations in patients with psoriasis. After treatment, concentrations of leptin and adiponectin were similar to those before treatment, while resistin was significantly lower (Kyriakou et al., 2018), suggesting that the change in resistin concentration has clinical significance in psoriatic patients. Therefore, these reports indicate that the relationship between adiponectin, resistin, and leptin is involved in the pathophysiology of psoriasis.

**OBESITY, LEPTIN, AND GRANULOCYTES**

Leptin acts as a type of survival cytokine in granulocytes. Neutrophils, eosinophils, and basophils have different forms...
Table 3. Effects of leptin on immune cells and cytokines involved in the pathogenesis of psoriasis

| Types                | Changes with increased leptin                                      | References |
|----------------------|----------------------------------------------------------------------|------------|
| Granulocytes         | Activated to promote pro-inflammatory cytokine secretion            | Lin et al., 2011; Suzukawa et al., 2011 |
| Monocytes            | Increased proliferation                                              | Santos-Alvarez et al., 1999 |
| Macrophages          | Increased number of M1 macrophages                                   | Acedo et al., 2013 |
| Dendritic cells (DCs)| Decreased apoptosis, which supports DC survival                     | Lam et al., 2006; Al-Hassi et al., 2013 |
| T cells              | Promoted CD4+ T cell polarization.                                   | Mattioli et al., 2005 |
| Th17 cells           | Increased number of cells                                            | Ortova and Shirshev, 2014 |
| T regulatory cells (Treg) | Suppressed proliferation                                             | De Rosa et al., 2007; Francisco et al., 2018 |
| TNF-α                | Increased expression                                                 | Santos-Alvarez et al., 1999 |
| IL-1β, IL-6, IL-12, IL-17 | Increased expression                                                 | Santos-Alvarez et al., 1999; Mattioli et al., 2008; Deng et al., 2012 |

Leptin affects various immune cells and cytokines involved in the pathogenesis of psoriasis. According to this table, psoriasis-related immune cells (granulocytes, monocytes, macrophages, DCs, and T cells) and pro-inflammatory cytokines (IL-6, IL-1β, IL-12, TNF-α, and IL-17) changed in response to increased leptin levels in manners favorable to psoriasis induction.

**OBESITY, LEPTIN, AND MONOCYTES/MACROPHAGES**

Functional LEPR is expressed in macrophages in the same way as other immune cells (O’Rourke et al., 2001). Leptin induces proliferation of human circulating monocytes, in vitro, and enhances their activation by inducing TNF-α and IL-6 production and stimulating surface markers (e.g., cluster of differentiation (CD) 25, HLA-DR, CD 38, CD 71) (Santos-Alvarez et al., 1999). Leptin treatment (50 ng/mL) of human macrophages induces “alternatively activated” or M2-phenotype surface markers that secret M1-phenotype cytokines (monocyte chemoattractant protein-1 (MCP-1), TNF-α, macrophage inflammatory protein 1-alpha (MIP-1α), IL-6, IL-1β, IL-1ra, and IL-10). Leptin has been found to affect macrophage phenotypes (Acedo et al., 2013). In particular, leptin-induced cytokine production (e.g., TNF-α, IL-6, IL-1β) by macrophages is related to psoriasis aggravation. Additionally, leptin induces M2 macrophages to express more LEPR, which stimulates more cytokine production in macrophages (Cao et al., 2016). Mast cells are also involved in leptin-induced macrophage regulation. In particular, both human and mouse mast cells from lean adipose tissue induce lower leptin expression compared with obese individuals. Anti-inflammatory activity of mast cells is promoted by leptin deficiency, which causes a shift in macrophage polarization from M1 to M2 (Zhou et al., 2015). In contrast, obese people with high leptin levels may have many M1 phenotype macrophages that can produce pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, consequently aggravating psoriasis.
**OBESITY, LEPTIN, AND DENDRITIC CELLS (DCS)**

Dendritic cells (DCs) are antigen-presenting cells of mammalian immune systems. Their main function is to process antigenic material and present it to T cells in the immune system. They serve as messengers between the innate and adaptive immune systems. Leptin is an activator of human DCs, as demonstrated by up-regulation of TNF-α, IL-1β, IL-6, IL-12, and MIP-1α, and by improvement of immature DC migration and chemotactic responsiveness. Leptin activation of human DCs prepares them for Th1 priming (Mattiolli et al., 2008). Moreover, leptin treatment supports DC survival through decreased apoptosis via activation of the NF-κB and PI3K-PKB signalings, together with an increase of bcl-2 and bcl-xL gene expression. LEPR-deficient db/db mouse bone marrow culture yielded a reduced number of DCs, which was attributable to dysregulation of the bcl-2 genes and a consequent increase in apoptosis (Lam et al., 2006; Al-Hassi et al., 2013). Several key studies that aimed to identify the initial psoriasis trigger demonstrated that injured keratinocytes enable coconatant myeloid dendritic cell (mDC)- and plasmacytoid dendritic cell (pDC)-driven immune events through LL37 nucleic acid complexes, which are heavily released in the psoriatic epidermis after skin trauma (Ganguly et al., 2009; Mattiolli et al., 2009; Lowes et al., 2013; Harden et al., 2015; Capon, 2017; Girolomoni et al., 2017). These multimeric LL37 nucleic acid complexes induce overproduction of type I IFN by pDC and of TNF-α and IL-6 by mDC (Albanesi et al., 2009). In addition, LL37 induces CXCL1 and CXCL8 chemokines by activating IL-36R signaling in psoriatic keratinocytes, which would, in turn, contribute to the neutrophil recruitment and bursting in lesional skin that is typical of early-phase psoriasis. Importantly, LL37 induces CCL20 and CXCL10 in psoriatic keratinocytes and is most likely responsible for the first flare of the acquired immunity established in later phases of psoriasis by DC and Th17.

**OBESITY, LEPTIN, AND T LYMPHOCYTES**

Skin is the organ where T cell-mediated inflammatory diseases such as psoriasis occur most often (Kim and Krueger, 2017). A psoriasis lesion begins after autoantigens, such as LL37/cathelicidin, ADAMTS5L5, and PLA2G4D-generated neo-lipid Ags, are recognized (Cheung et al., 2016). Next, the autoantigens present themselves within the DCs, allowing CD4+ T or CD8+ T cells to recognize the DCs. If an antigen is present within a DC with antigen MHC Type I, CD8+ T cells recognize it as being cytotoxic, which results in the cell being targeted for direct lysis. On the other hand, if an APC displays antigen using MHC Type II, CD4+ cells recognize it and become T helper cells (Th cells) that cause multiple downstream effects, including pro-inflammatory cytokine synthesis, which triggers psoriasis; IL-23, IL-17, IL22 instigate psoriasis in similar manners (Zinkernagel and Doherty, 1974; Katz et al., 1975; Goldrath and Bevan, 1999; Starr et al., 2003; von Boehmer et al., 2003). T cells have a long isoform of LEPR on their surface, which is much higher in peripheral CD4+ T cells than in CD8+ T cells (Sanchez-Margalet et al., 2002). In other words, if leptin is present, CD4+ T cells with many leptin receptors can differentiate into other cell types (Reis et al., 2015). In one example, differentiation of naive CD4+ T cells into Th17 cells occurs with the help of LEPR in vitro and in vivo. Similarly, leptin promotes CD4+ T cell polarization, resulting in a Th1 response (Mattiolli et al., 2005). The Th cells induced in psoriasis development are Th17, Th1, and Th22 cells, all of which secrete pro-inflammatory cytokines. Th17 cells play an important role in the early innate and acquired immunity (Albanesi et al., 2018). T regulatory cells (Treg) play an important role in the late phases of psoriasis, including amplification and chronicization (Wittamer et al., 2003). How these cell types affect psoriasis, and then how leptin, which is elevated under obesity conditions, can influence cell behavior are described below.

**OBESITY, LEPTIN, AND TH17 CELLS**

Th17 cells are derived from various types of DC cell populations. BDCA-1+DC, mature DC, and TIP-DC produce pro-inflammatory cytokines, foster Th17 cell differentiation (Hawkes et al., 2018). Once Th17 cells are activated, they induce expression of various psoriasis-inducing effector cytokines such as IL-26, IL-29, TNF-α, and IL17 (Wang et al., 2013a). Particularly, IL17-A and IL17-F, derived from Th17 cells directly affect the initial psoriasis phase. Various types of proteins (LL37/cathelicidin, LCN2, hBD2, and S100 proteins) that affect psoriasis are expressed from keratinocytes, while crucial cytokines are produced (Lande et al., 2014; Arakawa et al., 2015; Cheung et al., 2016). Additionally, IL-22, IL-19, and IL-36γ, which are made by inducing IL-17, cause epidermal hyperplasia, which makes the skin thick (Zaba et al., 2007). A feedforward inflammatory response plays a critical role in psoriasis development, and IL17 is at the center of this. In one example, IL17C, in response to IL-17 A/F, amplifies psoriasis-related genes, one of which induces Th17 cells to produce IL-17 A/F. Another dynamic in the positive feedback loop involves Th17 cell induction of STAT1 through IL-26 and IL-29, which foster psoriasis maintenance (Wolk et al., 2013; Stephen-Victor et al., 2016). Consequently, IL-17-producing Th17 cells play a crucial role in psoriasis promotion and maintenance. Several studies show that leptin is positively correlated with Th17 cells. In the autoimmune disease systemic lupus erythematosus (SLE), leptin promotes increased Th17 levels (Yu et al., 2013; Fujita et al., 2014; Reis et al., 2015). In a collagen-induced arthritis mouse model, the number of Th17 cells in the joint tissue increased after injecting leptin, which also increased disease severity (Deng et al., 2012). Leptin concentration in blood was found to be dramatically high during pregnancy (Henson and Castracane, 2000). Additionally, elevated leptin concentration is similar to concentrations found in pregnancy-promoted peripheral blood CD4C cells that differentiated into Th17 cells (Oriolva and Shirshev, 2014). In other words, Th17 cell counts were increased by leptin, which derived from CD4+ T cells, not just plasma leptin (Wang et al., 2013b). Furthermore, CD4+ T cells without LEPR only partially differentiated into Th17 cells (Reis et al., 2015). Leptin presence indicated that it plays a role in the differentiation process. In conclusion, it can be inferred that obesity-driven leptin might enhance Th17, consequently leading to severe psoriasis.

https://doi.org/10.4062/biomolther.2020.054
OBESITY, LEPTIN, AND T REGULATORY CELLS (TREG)

Treg cells are lymphocytes that contribute to regulation of excessive or autoimmune responses. They are able to directly interact with each other via the immune cell membrane receptor (memory and natural killer (NK) cells, B lymphocytes, effector T-lymphocytes, antigen-presenting cells) by producing suppressed cytokines (galectin-1, IL-10, TGF-β, IL-35,) or by direct cytotoxic action (granzyme B and perforin release) (Birch et al., 2005; Vignali et al., 2008). Obese individuals show a reduction in the number of CD4CD25CD127-Foxp3+ Treg cells, which correlates with body weight, BMI, and plasma leptin levels (Wagner et al., 2013). In humans, leptin had a negative effect on Foxp3CD4CD25+ Treg proliferation; in vitro leptin neutralization, during anti-CD3 and anti-CD28 stimulation, resulted in proliferation of isolated human Treg cells (De Rosa et al., 2007). Moreover, leptin-deficient mice have a higher number of peripheral Tregs than wild-type mice, but after inoculation with leptin, the trend reversed (De Rosa et al., 2007). Thus, leptin is found in greater abundance in obese people than in standard-body weight people, and it is considered that leptin has an inverse relationship with the number of Treg cells because the number of Tregs is lower in obese people. Pathogenesis is a chronic inflammatory disease induced by activation of the Th1/Th2 axis and an imbalance in the Th17/Treg axis (Deng et al., 2016). From the point of view of Treg cells and effector T cell number imbalance, T cell functionality and metabolism are closely related (MacIver et al., 2013); effector T cells, including Th1 and Th17, require a high glycolytic metabolism to support proliferation and function, while Treg cells require oxidative metabolism to support suppressive activity. Recently, in a mouse model of experimental autoimmune encephalomyelitis, leptin directly promoted glycolytic metabolism in T cells, which, in turn, induced Th17 cell differentiation, while Treg cells remained unchanged (Gerriets et al., 2016). Leptin upregulated the glucose transporter Glut1, thereby regulating glucose metabolism (Saucillo et al., 2014). Furthermore, the ability of T cells to secrete IL-2 and IFNγ was reduced during fasting, and glucose uptake and glycolytic systems could not be upregulated (Saucillo et al., 2014); meanwhile Treg levels increased (Liu et al., 2012). However, leptin treatment (1 mg/g body weight) recovered peripheral T cell metabolism and function in fasted mice (Saucillo et al., 2014). Synthetically, the above studies show the function of leptin to enhance immune activity by controlling T cell number and function. Leptin can induce proliferation of naive T cells and Th1 and Th17 cells and also increase cytokine production, but leptin suppressed Treg cell proliferation (Francisco et al., 2018). From this point of view, high leptin levels in obese people affect effector T cell and Treg function, which leads to abnormalities in the Th17/Treg balance, which could trigger psoriasis.

CONCLUSIONS

The mechanism by which obesity induces psoriasis is not fully understood. For this reason, many obese people suffer from psoriasis and are looking for effective treatments to improve it. Furthermore, there is no perfect cure for psoriasis. However, several studies have shown that leptin is produced at higher levels in the adipose tissue of obese people than in lean people. Leptin affects metabolism activation and the immune system, instigating inflammatory diseases like psoriasis. In this review, we suggest that leptin plays a central role in the correlation between obesity and psoriasis. Specifically, obesity-induced leptin secretion may be involved in psoriasis induction in the skin by altering a subpopulation of immune cells, as illustrated in Fig. 3. The role of immune cells in the development of psoriasis can be summarized as follows: in the early stage of psoriasis, innate immune cells secrete key cytokines that activate myeloid dendritic cells. Once dendritic cells are triggered by antigens, they secrete mediators such as IL-23. This induces differentiation of Th17, which produces pro-inflammatory cytokines like IL-17A. An IL-17A-triggered positive-feedback loop leads to the amplification/chronicization phase of psoriasis. During this phase, continuous activation between immune cells and keratinocytes increases in-

Fig. 3. The role of leptin in the association between obesity and psoriasis. Obese adipose tissue increases the production and secretion of leptin, which activates dendritic cells, granulocytes, macrophages, and T cells, consequently inducing psoriatic symptoms in the skin.
flammation severity. Also, this review implies that suppressing leptin production could be a possible approach for psoriasis therapy. However, more research is required to understand the pathophysiological functions of leptin in psoriasis development and the relationship between obesity and psoriasis. In addition, since pro-inflammatory cytokines are involved in the production of leptin molecules, it is important to investigate the possibility that psoriasis promotes adiposity and adipose inflammation.

CONFLICT OF INTEREST

The authors have declared no conflict of interest.

ACKNOWLEDGMENTS

This study was supported by a grant from Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and Technology Information and Communication (Grant No. 2020R1F1A1067731).

REFERENCES

Acedo, S. C., Gambero, S., Cunha, F. G., Lorand-Metze, I. and Gambero, A. (2013) Participation of leptin in the determination of the macrophage phenotype: an additional role in adipocyte and macrophage crosstalk. In Vitro Cell. Dev. Biol. Anim. 49, 473-478.

Ahima, R. S. and Flier, J. S. (2000) Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 11, 327-332.

Ahmad, R., Thomas, R., Kochumon, S. and Sindhu, S. (2017) Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity. Immun. Inflamm. Dis. 5, 518-335.

Al-Hassi, H. O., Bernardo, D., Muruganathan, A. U., Mann, E. R., English, N. R., Jones, A., Kamm, M. A., Arefi, N., Hart, A. L., Blake-more, A. I., Stagg, A. J. and Knight, S. C. (2013) A mechanistic role for leptin in human dendritic cell migration: differences between il-12 and col in eum and col in health and Crohn’s disease. Mucosal Immunol. 6, 751-761.

Al-Suhaimi, E. A. and Shehazad, A. (2013) Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur. J. Med. Res. 18, 12.

Albanesi, C., Madonna, S., Gisondi, P. and Girolomoni, G. (2018) The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front. Immunol. 9, 1549.

Albanesi, C., Scarponi, C., Pallotta, S., Daniele, R., Bosiolo, D., Madonna, S., Fortugno, P., Gonzalvo-Feo, S., Franssen, J. D., Parent, M., De Plâtê, O., Girolomoni, G. and Sozann, S. (2009) Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J. Exp. Med. 206, 249-258.

Arakawa, A., Siewert, K., Stihr, J., Besgen, P., Kim, S. M., Röhl, G., Nickel, J., Vollmer, S., Thomas, P., Kresbs, S., Pinkert, S., Spannegl, M., Held, K., Kammerbauer, C., Besch, R., Dormnair, K. and Prinz, J. C. (2015) Melanocyte antigen triggers autoimmunity in human psoriasis. J. Exp. Med. 212, 2203-2212.

Ballistri, C. R., Caruso, C. and Candore, G. (2010) The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010, 802078.

Benomar, Y., Gartner, A., De Lacy, P., Crépin, D., Hamouda, H. O., Riffault, L. and Taouis, M. (2013) Central resistin overexpression induces insulin resistance through Toll-like receptor 4. Diabetes 62, 102-114.

Birch, K. E., Vukmanovic-Stejic, M., Reed, J. R., Akbar, A. N. and Rustin, M. H. (2005) The immunomodulatory effects of regulatory T cells: implications for immune regulation in the skin. Br. J. Dermatol. 152, 409-417.

Cao, H., Lin, J., Chen, W., Xu, G. and Sun, C. (2016) Baseline adiponectin and leptin levels in predicting an increased risk of disease activity in rheumatoid arthritis: a meta-analysis and systematic review. Autoimmunity 49, 547-553.

Capon, F. (2017) The genetic basis of psoriasis. Int. J. Mol. Sci. 18, 2526.

Chang, J. S., Chang, C. C., Chien, E., Lin, S. S., Cheng-Shiu, T., Bai, C. H. and Chao, K. C. (2013) Association between interleukin 1beta and interleukin 10 concentrations: a cross-sectional study in young adolescents in Taiwan. BMC Pediatr. 13, 123.

Cheung, K. L., Jarrett, R., Subramaniam, S., Salimi, M., Goutowska-Owiaski, D., Chen, Y. L., Hardman, C., Xue, L., Cerundolo, V. and Ogg, G. (2016) Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J. Exp. Med. 213, 2399-2412.

Cristancho, A. G. and Lazar, M. A. (2011) Forming functional fat: a growing understanding of adipocyte differentiation. Nat. Rev. Mol. Cell Biol. 12, 722-734.

de Heredia, F. P., Gómez-Martínez, S. and Marcos, A. (2012) Obesity, inflammation and the immune system. Proc. Nutr. Soc. 71, 332-353.

De Rosa, V., Procaccini, C., Cali, G., Pirozzi, G., Fontana, S., Zappacosta, S., La Cava, A. and Matarese, G. (2007) A key role of leptin in the control of regulatory T cell proliferation. Immunity 26, 241-255.

Deng, J., Liu, Y., Yang, M., Wang, S., Zhang, M., Wang, X., Ko, K. H., Hu, Z., Sun, L., Cao, X. and Lu, L. (2012) Leptin exacerbates collagen-induced arthritis via enhancement of Th17 cell response. Arthritis Rheum. 64, 3564-3573.

Deng, Y., Chang, C. and Lu, Q. (2016) The inflammatory response in psoriasis: a comprehensive review. Clin. Rev. Allergy Immunol. 50, 377-389.

Ennor, P. J., Evans, A. E., Sinnayah, P. and Cowley, M. A. (2006) Leptin resistance and obesity. Obesity (Silver Spring) 14, 254S-258S.

Esposito, K., Pontillo, A., Giugliano, F., Giugliano, G., Marfella, R., Nicoleti, G. and Giugliano, D. (2003) Association of low interleukin-10 levels with the metabolic syndrome in obese women. J. Immunol. 167, 1549.

Fain, J. N. (2010) Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm. 2010, 513948.

Francisco, V., Pino, J., Campos-Cabaleiro, V., Ruiz-Fernandez, C., Mera, A., Gonzalez-Gay, M. A., Gomez, R. and Guallio, O. (2018) Obesity, fat mass and immune system: role for leptin. Front. Physiol. 9, 540.

Fredriksen, T. and Pettersson, U. (1978) Severe psoriasis--oral therapy with a new retinoid. Dermatologica 157, 238-244.

Fujita, Y., Fujii, T., Mimori, T., Sato, T., Nakamura, T., Iwao, H., Nakajima, A., Miki, M., Sakai, T., Kawanami, T., Tanaka, M., Masaki, Y., Fukushima, T., Okazaki, T. and Umeheara, H. (2014) Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas ip mice. J. Immunol. 192, 979-984.

Ganguly, D., Chamilos, G., Lande, R., Gregorio, J., Meller, S., Facchinetti, V., Homey, B., Barrat, F. J., Zai, T. and Gilliet, M. (2009) Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 206, 1983-1994.

Gerriets, V. A., Danzaki, K., Kishton, R. J., Eisner, W., Nichols, A. G., Mera, A., Gonzalez-Gay, M. A., Gomez, R. and Guallio, O. (2018) Obesity, fat mass and immune system: role for leptin. Front. Physiol. 9, 540.

Girolomoni, G., Strohal, R., Subramaniam, S., Salimi, M., Goutowska-Owiaski, D., Chen, Y. L., Hardman, C., Xue, L., Cerundolo, V. and Ogg, G. (2016) Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. J. Exp. Med. 213, 2399-2412.

Goldrath, A. W. and Bevan, M. J. (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402, 255-262.
Guzik, T., Mangalat, D. and Korbut, R. (2006) Adipocytokines novel
Gruzdeva, O., Borodkina, D., Uchasova, E., Dyleva, Y. and Barbarash,
Griffiths, C. E., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort,
Hawkes, J. E., Yan, B. Y., Chan, T. C. and Krueger, J. G. (2018) Dis-
Harden, J. L., Krueger, J. G. and Bowcock, A. M. (2015) The immu-
Huh, J. Y., Park, Y. J., Ham, M. and Kim, J. B. (2014) Crosstalk be-
Kyriakou, A., Patsatsi, A., Sotiriadis, D. and Goulis, D. (2018) Effects
Kunze, A., Forster, U., Oehrl, S., Schmitz, M. and Schakel, K. (2017)
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C.,
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, Y. J., Riblett, M., Yala-
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E. and Krueger,
Lundberg, D., Haggblom, P., Khan, R. B., Gordon, S. I., Lagercrantz, H.,
Lung, Y., Zmora, N., Briasoulis, A., De Groot, J. H., Lee, J., Seok, J. E.,
Luscher, T. F., Hynynen, K. M., Conrad, D. J., Allewell, N. M., Lo, C.,
Lye, M., Norkus, E. P., Xi, Y., Lemanske, R. F., Hayden, M. F., Sorkin,
Luh, S. Y., Pham, Y., Kim, Y. J., Choi, J. A., Park, J. Y., Ahn, J. W.,
Lundberg, D., Haggblom, P., Khan, R. B., Gordon, S. I., Lagercrantz, H.,
Luscher, T. F., Hynynen, K. M., Conrad, D. J., Allewell, N. M., Lo, C.,
Lye, M., Norkus, E. P., Xi, Y., Lemanske, R. F., Hayden, M. F., Sorkin,
Lundberg, D., Haggblom, P., Khan, R. B., Gordon, S. I., Lagercrantz, H.,
Luscher, T. F., Hynynen, K. M., Conrad, D. J., Allewell, N. M., Lo, C.,
Lye, M., Norkus, E. P., Xi, Y., Lemanske, R. F., Hayden, M. F., Sorkin,
C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y., Elmets, C. A., Korman, N. J., Beutner, K. R. and Bhushan, R. (2008a) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 58, 826-850.

Menter, A., Tyring, S. K., Gordon, K., Kimmall, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M. and Papp, K. (2008b) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J. Am. Acad. Dermatol. 58, 106-115.

Mohamed-Al, V., Pinkney, J. and Coppack, S. (1998) Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22, 1145-1158.

Münzberg, H. and Morrison, C. D. (2015) Structure, production and signalling of leptin. Metabolism 64, 13-23.

Myers, M. G., Jr., Leibel, R. L., Seeley, R. J. and Schwartz, M. W. (2010) Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol. Metab. 21, 643-651.

Naldi, L., Addis, A., Chimenti, S., Giannetti, A., Piccardo, M., Tomino, C., Maccarone, M., Chatenoud, L., Bentuccio, P., Caggese, E. and Cuscito, R. (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217, 365-373.

O’Rourke, L., Yeaman, S. J. and Shepherd, P. R. (2001) Insulin and leptin acutely regulate cholesterol ester metabolism in macrophages by novel signaling pathways. Diabetes 50, 955-961.

Onuma, H., Tabara, Y., Kawamura, R., Ohashi, J., Nishida, W., Takata, Y., Ochi, M., Nishimiyama, T., Kawamoto, R., Kohara, K., Miki, T. and Osawa, H. (2013) Plasma resistin is associated with single nucleotide polymorphisms of a possible resistin receptor, the decorin gene, in the general Japanese population. Diabetes 62, 649-652.

Orlova, E. G. and Shirshev, S. V. (2014) Role of leptin and ghrelin in induction of differentiation of IL-17-producing and T-regulatory cells. Bull. Exp. Biol. Med. 158, 819-822.

Ouchi, N., Higuchi, A., Ohashi, K., Oshima, Y., Gokce, N., Shibata, R., Akasaka, Y., Shimonou, A. and Walsh, K. (2010) Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329, 454-457.

Ouchi, N., Ohashi, K., Shibata, R. and Murohara, T. (2012) Adipocytokines and obesity-linked disorders. Naga.ya. J. Med. Sci. 74, 19-30.

Ouchi, N., Parker, J. L., Lugus, J. J. and Walsh, K. A. (2011) Adipokines in inflammation and metabolic disease. Nature Rev. Immunol. 11, 85-97.

Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R. G., Krueger, J. G., Gottlieb, A. B., Nakagawa, H., Bowman, E. P., Mehta, A., Li, Q., Zhou, Y. and Shames, R. (2015) Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase Ib randomized placebo-controlled trial. Br. J. Dermatol. 173, 930-939.

Papp, K. A., Laneély, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yelindo, J., Guzzo, C., Hsu, M. C., Wang, Y., Li, S., Dooley, L. T. and Reich, K.; PHOENIX 2 study investigators (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684.

Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E., Nakashima, A. M., Zitnik, R., van de Kerkhof, P. C. and Melvin, L.; Etanercept Psoriasis Study Group (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304-1312.

Paris, R., Symmons, D. P., Griffiths, C. E. and Ashcroft, D. M.; Identification and Management of Psoriasis and Associated Comorbidities (IMPACT) project team (2013) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133, 377-385.

Poeggeler, B., Schulz, C., Poppolla, M. A., Bodö, E., Tiede, S., Lehner, H. and Paus, R. (2010) Leptin and the skin: a new frontier. Exp. Dermatol. 19, 12-18.

Pujanek, M., Bronisz, A., Malecki, P. and Junik, R. (2013) Pathomechanisms of the development of obesity in some endocrinopathies - an overview. Endokrynol. Pol. 64, 150-155.

Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R., Guzzo, C., Li, S., Dooley, L. T. and Griffiths, C. E.; EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366, 1367-1374.

Reis, B. S., Lee, K., Fanok, M. H., Mascarà, C., Amouy, M., Cohn, L. B., Rogoz, A., Dallner, O. S., Moraes-Vieira, P. M., Domingos, A. J. and Mucida, D. (2015) Leptin receptor signaling in T cells is required for Th17 differentiation. J. Immunol. 194, 5253-5260.

Rosenbaum, M. and Leibel, R. L. (2014) 20 years of leptin: role of leptin in energy homeostasis in humans. J. Endocrinol. 223, T83-T96.

Sáinz, N., Barrenetxe, J., Moreno-Aliaga, M. J. and Martínez, J. A. (2015) Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 64, 35-46.

Sakai, R., Matsu, S., Fukushima, M., Yasuda, H., Miyauchi, H. and Miyachi, Y. (2005) Prognostic factor analysis for plaque psoriasis. Dermatology 211, 103-106.

Sanchez-Margalef, V., Martin-Romero, C., Gonzalez-Yanes, C., Goberna, R. and Rodriguez-Bano, J.; Muniaín, M. A. (2002) Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells by in vitro activation and in vivo in HIV-infected patients. Clin. Exp. Immunol. 129, 119-124.

Santos-Alvarez, J., Goberna, R. and Sanchez-Margalef, V. (1999) Human leptin stimulates proliferation and activation of human circulating monocytes. Cell. Immunol. 194, 6-11.

Saucillo, D. C., Gerretis, V. A., Sheng, J., Rathmell, J. C. and Maciver, N. J. (2014) Leptin metabolically licenses T cells for activation to link nutrition and immunity. J. Immunol. 192, 134-144.

Saurat, J. H., Stingl, G., Dubertret, L., Papp, K., Langley, R. G., Ortonne, J. P., Unnebrink, K., Kaul, M. and Cazez-A; CHAMPION Study Investigators (2008) Efficacy and safety results from the randomised controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 158, 558-566.

Schenk, S., Saberi, M. and Olausky, J. M. (2008) Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118, 2992-3002.

Schon, M. P., Broeckaert, S. M. and Erpenbeck, L. (2017) Sexy again: the renaissance of neutrophils in psoriasis. Exp. Dermatol. 26, 305-311.

Scoetece, M., Conde, J., López, V., Lago, F., Pino, J., Gómez-Reino, J. J. and Guallitol, O. (2014) Adiponectin and leptin: new targets in inflammation. Basic Clin. Pharmacol. Toxicol. 114, 97-102.

Starr, T. K., Jameson, S. C. and Hoggquist, K. A. (2003) Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176.

Stephen-Victor, E., Fickenscher, H. and Bayry, J. (2016) IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial, and autoimmune responses. PLoS Pathog. 12, e1005624.

Stern, R. S.; PUVA Follow up Study (2001) The risk of melanoma in association with long-term exposure to PUVA. J. Am. Acad. Dermatol. 44, 755-761.

Sun, Z., Dragon, S., Becker, A. and Gounni, A. S. (2013) Leptin inhibits its neutrophil apoptosis in children via ERK/KN-kappab-dependent pathways. PLoS ONE 8, e55249.
selection revisited: how essential is it? Immunol. Rev. 191, 62-78.
Wagner, N. M., Brandhorst, G., Czepluch, F., Lankeit, M., Eberle, C., Herzberg, S., Faustin, V., Riggert, J., Oellerich, M., Hasenfuss, G., Konstantinides, S. and Schäfer, K. (2013) Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity (Silver Spring) 21, 461-468.
Wang, C. Q., Akalu, Y. T., Suarez-Farinas, M., Gonzalez, J., Mitsui, H., Lowes, M. A., Orlow, S. J., Manga, P. and Krueger, J. G. (2013a) IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J. Invest. Dermatol. 133, 2741-2752.
Wang, S., Baidoo, S. E., Liu, Y., Zhu, C., Tian, J., Ma, J., Tong, J., Chen, J., Tang, X., Xu, H. and Lu, L. (2013b) T cell-derived leptin contributes to increased frequency of T helper type 17 cells in female patients with Hashimoto’s thyroiditis. Clin. Exp. Immunol. 171, 63-68.
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L. and Ferrante, A. W., Jr. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808.
Wittamer, V., Fransson, J. D., Vulcano, M., Mirjolet, J. F., Le Poul, E., Migeotte, I., Brézillon, S., Tyldesley, R., Blanpain, C., Dethieux, M., Mantovani, A., Sozzani, S., Vassart, G., Parmentier, M. and Comnuni, D. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977-985.
Wolk, K., Witte, K., Witte, E., Raftery, M., Kokolakis, G., Philipp, S., Schönrich, G., Warszawski, K., Kirsch, S., Prösch, S., Sterry, W., Volk, H. D. and Sabat, R. (2013) IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci. Transl. Med. 5, 204ra129.
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A. and Chen, H. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830.
Yang, R. and Barouch, L. A. (2007) Leptin signaling and obesity: cardiovascular consequences. Circ. Res. 101, 545-559.
Ye, J. and McGuinness, O. P. (2013) Inflammation during obesity is not all bad: evidence from animal and human studies. Am. J. Endocrinol. Metab. 304, E466-E477.
Yu, Y., Liu, Y., Shi, F. D., Zou, H., Matarese, G. and La Cava, A. (2013) Cutting edge: Leptin-induced RORgammat expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J. Immunol. 190, 3054-3058.
Zaba, L. C., Cardinale, I., Gilleaudteau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A. and Krueger, J. G. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183-3194.
Zhou, Y. and Rui, L. (2013) Leptin signaling and leptin resistance. Front. Med. 7, 207-222.
Zhou, Y., Yu, X., Chen, H., Sjöberg, S., Roux, J., Zhang, L., Ivoulsou, A. H., Bensaid, F., Liu, C. L., Liu, J., Tordjman, J., Clement, K., Lee, C. H., Hotamisligil, G. S., Libby, P. and Shi, G. P. (2015) Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 22, 1045-1058.
Zinkernagel, R. M. and Doherty, P. C. (1974) Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701-702.